Ticker brief
RGNX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
18
authors 14d
12
crowd 14d
-1.5σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 80% | HV n/a |
| Skew — 25Δ RR 30d | +0.030 | 25Δ call IV − put IV |
| OI alarm | quiet | last alarm 2026-06-23 (z=17.2) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-24 → 2026-08-28 · now +0.00 (−1 bearish … +1 bullish)
Who spoke12
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | -0.43 |
| @PersimmonTI | A | -0.57 | 2 | -0.33 |
| @BioStocks | C | -3.02 | 2 | -0.45 |
| @Chill_Investing | C | -1.24 | 2 | +0.00 |
| @MktBrain_US | C | -0.78 | 1 | -0.50 |
| @OpenOutcrier | C | · | 1 | -0.50 |
| @BPharmCatalyst | C | · | 1 | -0.50 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @fwpharma | B | +0.98 | 1 | -0.50 |
| @EmmanuelInvest | C | -1.11 | 1 | +0.10 |
| @BeatTheInsider | C | · | 1 | +0.30 |
| @doublejtrading | C | -1.82 | 1 | +0.00 |
Recent signals18of 18 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Chill_Investing | +0.00 | Introduces a closing-bell recap of premarket movers, but results are only in inaccessible media. | · | tweet ↗ |
| 2026-08-28 | @Chill_Investing | +0.00 | Premarket mover list names gainers and losers but text does not map direction to individual tickers. | · | tweet ↗ |
| 2026-08-28 | @doublejtrading | +0.00 | Premarket gapper watchlist without stated direction for individual names. | · | tweet ↗ |
| 2026-08-27 | @BeatTheInsider | +0.30 | Reports an insider purchase of 102,603 RGNX shares worth $949,381.45. | · | tweet ↗ |
| 2026-08-25 | @EmmanuelInvest | +0.10 | REGENXBIO appointed Greg Ciongoli to its board as two directors retire. | · | tweet ↗ |
| 2026-08-25 | @BioStocks | -0.40 | Baird maintained Outperform on RGNX but cut its price target to $29. | · | tweet ↗ |
| 2026-08-24 | @PersimmonTI | -0.15 | Expresses skepticism about the company's public-relations behavior. | · | tweet ↗ |
| 2026-08-24 | @fwpharma | -0.50 | Spinal masses represent another reported setback for Regenxbio's gene therapy. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.50 | Summarizes four biotech regulatory or clinical catalysts and corresponding price moves. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.50 | Reports RGNX falling about 25% after FDA placed RGX-121 on clinical hold. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.50 | Dense biotech news list covering approvals, FDA actions, dosing and a reverse split. | · | tweet ↗ |
| 2026-08-24 | @OzmosiHealth | +0.00 | REGENXBIO announced an unspecified regulatory update for RGX-121. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.20 | Balances an FDA clinical hold against later DMD and AMD catalysts, calling RGNX high-risk but catalyst-rich. | · | tweet ↗ |
| 2026-08-24 | @BPharmCatalyst | -0.50 | FDA places RGX-121 on clinical hold after spinal MRI findings, delaying BLA resubmission. | · | tweet ↗ |
| 2026-08-24 | @OpenOutcrier | -0.50 | FDA placed RGX-121 on clinical hold. | · | tweet ↗ |
| 2026-08-24 | @MktBrain_US | -0.50 | Premarket roundup covers offerings, an acquisition, an earnings beat and an FDA clinical hold. | · | tweet ↗ |
| 2026-08-24 | @BioStocks | -0.50 | FDA placed RGX-121 on clinical hold and the company no longer expects a near-term BLA resubmission. | · | tweet ↗ |
| 2026-08-24 | @PersimmonTI | -0.50 | FDA placed RGX-121 on hold after MRI findings and a near-term BLA resubmission is not expected. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.